A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
NCT ID: NCT01100502
Last Updated: 2021-05-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
329 participants
INTERVENTIONAL
2010-04-30
2020-04-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
NCT00947856
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
NCT01990534
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
NCT00848926
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
NCT04334174
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01508312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Brentuximab vedotin
brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
brentuximab vedotin
Every 21 days by IV infusion (1.8 mg/kg)
Placebo
placebo every 3 weeks by IV infusion
placebo
Every 21 days by IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
brentuximab vedotin
Every 21 days by IV infusion (1.8 mg/kg)
placebo
Every 21 days by IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients at high risk of residual HL post ASCT
* Histologically-confirmed HL
* ECOG of 0 or 1
* Adequate organ function
Exclusion Criteria
* Previously received an allogeneic transplant
* Patients who were determined to have a best clinical response of progressive disease with salvage treatment immediately prior to ASCT
* History of another primary malignancy that has not been in remission for at least 3 years
* Post ASCT or current therapy with other systemic anti-neoplastic or investigational agents
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Millennium Pharmaceuticals, Inc.
INDUSTRY
Seagen Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julie Lisano, PharmD
Role: STUDY_DIRECTOR
Seagen Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope National Medical Center
Duarte, California, United States
University of California at San Francisco
San Francisco, California, United States
Stanford Cancer Center
Stanford, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Northside Hospital
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
University of Chicago Section of Hematology/Oncology Lymphoma Program
Chicago, Illinois, United States
Cardinal Bernardin Cancer Center / Loyola University Medical Center
Maywood, Illinois, United States
Indiana University School of Medicine Simon Cancer Center 535 Barnhill Drive, RT 380
Indianapolis, Indiana, United States
Johns Hopkins Medical Center
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Karmanos Cancer Institute / Wayne State University
Detroit, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
New York University Cancer Institute
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
UNC Lineberger Comprehensive Cancer Center / University of North Carolina
Chapel Hill, North Carolina, United States
Cleveland Clinic, The
Cleveland, Ohio, United States
James Cancer Hospital / Ohio State University
Columbus, Ohio, United States
Oregon Health and Science University / Center for Hematologic Malignancies
Portland, Oregon, United States
Temple Bone Marrow Transplant Program
Philadelphia, Pennsylvania, United States
Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States
Saint Francis Hospital
Greenville, South Carolina, United States
Cancer Center of the Carolinas
Greenville, South Carolina, United States
Baylor University Medical Center
Dallas, Texas, United States
MD Anderson Cancer Center / University of Texas
Houston, Texas, United States
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Specializirana bolnica aktivno lechenie detsa ohcohematologichni zabolyavania Hematologichno
Sofia, , Bulgaria
Specializirana bolnica za aktivno lechenie na hematologichni zabolyavania
Sofia, , Bulgaria
Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie
Hradec Králové, , Czechia
Fakultni nemocnice Kralovske Vinohrady-oddeleni klinicke hematologie
Prague, , Czechia
Vseobecni fakultni nemocnice v Prahe-I. interni klinika
Prague, , Czechia
CHU Nantes - Hopital Hotel Dieu Service Hematologie
Nantes, , France
Service des Maladies du Sang / Hospital Saint Louis
Paris, , France
CHU Bordeaux Hopital Haut-Levaque
Pessac, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Centre Henri Becquerel / Centre Regional de Lutte Contre le Cancer
Rouen, , France
University Hospital of Cologne
Cologne, , Germany
Szent Istvan es Szent Laszlo Korhaz Rendelointezet Haematologiai es Ossejt-transzplantacios osztaly
Budapest, , Hungary
Debreceni Egyetem Orvos és Egeszsegtudomanyi Centrum, III. sz. Belgyogyaszati Klinika
Debrecen, , Hungary
Medical Center of the University of Pecs, 1st Clinic for Internal Medicine
Pécs, , Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikat Kozpont
Szeged, , Hungary
Instituto di Ematologia ed Oncologia Medica
Bologna, , Italy
Azienda Ospedaliera Universitaria San Martino
Genova, , Italy
Istituto Nazionale dei Tumori
Milan, , Italy
Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne
Gdansk, , Poland
Oddzial Transplantacji Szpiku Centrum Onkologii- Instytut M. Sklodowskiej-Curie, Oddzial Gliwicach
Gliwice, , Poland
Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mieleckiego Slaskiego Uniwersytetu Medycznego
Katowice, , Poland
Szpital Uniwersytecki w Krakowie
Krakow, , Poland
Klinika Hematologii, Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
Lodz, , Poland
Oddzial Hematoonkologii, Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie
Lublin, , Poland
MTZ Clinical Research Sp. z o.o.
Warsaw, , Poland
Klinika Hematologii, Instytut Hematologii i Transfuzjologii
Warsaw, , Poland
Centrum Onkologii Institut im. Marii Sklodowskiej-Curie
Warsaw, , Poland
Spitalul Clinic Judetean de Urgenta Targu Mures, Sectia Clinica Hematologie si Transplant Medular
Târgu Mureş, Mureș County, Romania
Spitalul Clinic de Urgenta pentru Copii Louis Turcanu, Clinica III Pediatrie
Timișoara, Timiș County, Romania
Fundeni Clinical Institute
Bucharest, , Romania
Institutul Clinic Fundeni, Centrul de Hematologie si Transplant Medular Stefan Berceanu
Bucharest, , Romania
Burdenko Central Military Clinical Hospital
Moscow, , Russia
Rossijskij onkologicheskij nauchnyj centr im. N.N. Blokhina RAMN
Moscow, , Russia
Federal Medical Biophysical Center n.a. A.I. Burnazyan
Moscow, , Russia
Gematologicheskj nauchnyj centr RAMN
Moscow, , Russia
Uchrezhdenie Rossijskoj nauk Nauchno-issledovatel'skij institut klinicheskoj immunologii
Novosibirsk, , Russia
Respublikanskaja bol'nica im. V.A. Baranova
Petrozavodsk, , Russia
Leningradskaja oblastnaja klinicheskaja bol'nica
Saint Petersburg, , Russia
Sankt-Peterburgskij gosudarstvennyj medicinskij universitet im. akademika I. P. Pavlova
Saint Petersburg, , Russia
St. Petersburg Pavlov State Medical University
Saint Petersburg, , Russia
Gorodskaya bol'nica #31
Saint Petersburg, , Russia
Federal Center of Heart, Blood and Endocrinology n.a. V.A. Almazov under the Federal Agency for High
Saint Petersburg, , Russia
Sverdlovskaja oblastnaja klinicheskaja bol'nica #1
Yekaterinburg, , Russia
Klinicki centar Srbije, Klinika za hematologiju
Belgrade, , Serbia
Vojnomedicinska akademija, Klinika za hematologiju
Belgrade, , Serbia
Klinicko bolnicki centar "Vojvodina", Klinika za hematologiju
Novi Sad, , Serbia
Complejo Hospitalano de Navarra Servicio Hematologia
Pamplona, Navarre, Spain
Hospital de la Santa Creu i Sant Paul
Barcelona, , Spain
Hospital Clinic i Provincial Servicio Hematologia
Barcelona, , Spain
Centro Oncologico MD Anderson
Madrid, , Spain
Hospital Universitaro de Salamanca
Salamanca, , Spain
Addenbrooke's Hospital
Cambridge, , United Kingdom
St James University Hospital
Leeds, , United Kingdom
Guy's Hospital Haematology Department, 4th Floor Southwark Wing
London, , United Kingdom
Christie Hospital NHS Foundation Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018 Dec 20;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641. Epub 2018 Sep 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-016947-20
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
SGN35-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.